We are surrounded by food that is contaminated, adulterated and does not meet Indian safety and packaging standards, says Abheet Singh Sethi/IndiaSpend.com.
Ranbaxy drugs sold in the United States will be gradually rebranded as Sun Pharma treatments
The procedure, however, would cost around Rs 75,000-100,000 more than conventional angioplasty.
India and the US should not get into any lengthy investigations for business related concerns.
Experts question Nestle's silence over Maggi controversy.
Gujarat has around 3,000 licensees for allopathic drug manufacturing, apart from around seven homeopathic licensees, 500 ayuvedic and 600-700 cosmetics licensees
Maggi banned in Delhi for 15 days.
The introduction of e-pharmacy, to protect the interest of a handful of players, would hamper the interest of 800,000 chemists and 80 lakh workers and their families
The state government had in the first week of June banned Maggi sale in the state after the product failed the food safety test.
Financials were the top losers while oil shares also declined amid weak crude oil prices.
'Let me talk about young Indian startups with their hearts in the right place and how they are proving that innovations that represent 'affordable excellence' -- breaking the myth that 'affordability' and 'excellence' cannot go together -- is indeed possible!' says Dr R A Mashelkar, the eminent scientist, in this fascinating feature.
Punishing brand ambassadors shows that the government is only interested in going after the low hanging fruit, says Tanmaya Nanda.
The broader markets ended negatively with mid-caps and small-caps shedding 0.5 per cent on the BSE.
Kapiva's plans to introduce allopathy-like doses of ayurvedic remedies for the millennial consumer finds traction.
Check out some of the stocks that will react on the basis of their numbers in the near term.
A huge stock of Maggi noodles was destroyed by Nestle after the ban was imposed by the food regulators.
The company spokesperson expressed disappointment with the "unprecedented step of filing of a complaint before the NCDRC"
In its daily briefing, the government also reported Goa is now free of coronavirus.
Investment in market leaders with a safety-first approach could yield reasonable returns across sectors.
It hopes to turn around Ranbaxy within four years of closing the deal by improving efficiency and resolving all regulatory issues
The 50-share NSE Nifty stayed in the positive zone and retook the 9,900-mark to hit a high of 9,905.05 as buying paced up towards the fag end. It settled higher by 72.45 points, or 0.74 per cent, at 9,899.60.
The recalled drug bottles were distributed by Caraco Pharmaceutical Laboratories, Ltd in the US while manufactured in India by Sun Pharmaceutical Industries Ltd.
Its Waluj manufacturing facility in Maharashtra failed to meet the good manufacturing norms prescribed by the UK drug regulator.
Nestle now has less than two weeks to convince the regulator why product approval for its noodles should not be withdrawn
In the Sensex pack, ICICI Bank emerged as the top gainer by rising 0.97 per cent, while Tata Steel advanced 0.92 per cent.
While the US health regulator did not specify details for issuing the alert, it said 'detention without physical examination may be appropriate when an FDA inspection has revealed that a firm is not operating in conformity with current good manufacturing practices'.
Lack of clarity on whether manufacturing bans in Punjab, Uttarakhand, Himachal, Goa and Karnataka still in place
Amneal Pharmaceuticals is set to pip Sun Pharma as the fifth largest generics maker in the US, reports Sohini Das.
It was a disturbing message in the sense that the regulatory framework is not clear enough and is not always applied in a convincing manner.
In India, thousands of lives are lost every year because of unavailability of organs
Competition in the US pharmaceutical market swelled in recent years, with increasing generic penetration.
IT, pharma and FMCG stocks are the top performers in 2013.
'The mismatch between valuations and fundamentals is startling,' warns Devangshu Datta
DRL launched four new products in North America during the previous quarter.
Sun Pharma profit down 30% over compliance costs, lower sales.
4 Ranbaxy facilities in India have been barred from exporting to US.
.jpg)
The report comes at a time when the government is trying to clear pending FDI proposals, which include various planned investments in this sector.
In a surprise announcement in April, Sun and Ranbaxy -- at that time owned by Japan's Daiichi -- declared an all-stock deal to create India's largest and world's fifth-largest drugmaker in an over $4 billion deal.
